EIDX - Eidos Therapeutics: Differentiated Market High Stock Price But Solid Potential In The Long Run

TTR amyloidosis or ATTR is a protein misfolding disease that has received a lot of attention over the last couple of years, with the approval of Alnylam’s (ALNY) first RNAi therapy Onpattro/patirisan in this indication. A number of other therapies are in late stages, with Pfizer’s (PFE) tafamidis about to see its PDUFA in November this year. There are other companies, as a fellow Seeking Alpha author has covered: “Other competitors in the clinic include Ionis’ (NASDAQ: IONS) Tegsedi, Pfizer's ((PFE)) tafamidis, Eidos' (NASDAQ: EIDX) AG10, GSK's (NYSE:

Read more ...